CJC-1295 with DAC
Also known as: CJC-1295 DAC, DAC:GRF, Drug Affinity Complex GRF
A long-acting growth hormone releasing hormone analog with a Drug Affinity Complex (DAC) that binds to albumin in the blood, extending the half-life to 6-8 days. This means it provides continuous GH elevation rather than pulsed release. Originally developed by ConjuChem Biotechnologies.
How it works
CJC-1295 with DAC is a modified version of GHRH (growth hormone releasing hormone). The DAC molecule binds to albumin protein in your blood, which prevents the peptide from being broken down quickly. This extends its half-life to 6-8 days, meaning a single injection can keep GH levels elevated for about a week. It boosts GH 2-10x above baseline for 6+ days and IGF-1 for 9-11 days.
Common uses
- Sustained growth hormone elevation
- Body composition (fat loss, lean mass)
- Anti-aging and recovery
- Sleep quality improvement
- Often combined with a GHRP like ipamorelin for stronger effects
Side effects
- Water retention and bloating
- Headache
- Flushing
- Tingling or numbness in hands and feet
- Joint pain or stiffness
- Injection site reactions
- Potential for constant (non-pulsatile) GH elevation, which some doctors consider less ideal than natural pulsing
Key research
- Clinical studies showed GH levels elevated 2-10x baseline for 6+ days after a single injection
- IGF-1 levels increased 0.5-3x for 9-11 days after injection
- Phase 2 clinical trials for lipodystrophy and GH deficiency were conducted but discontinued after a participant death (cause debated)
- Daily dosing shown to normalize growth in GHRH knockout mice
Safety notes
- Not FDA-approved for any therapeutic use
- Phase 2 trials were halted after a participant death, though the connection to CJC-1295 was debated
- The continuous GH elevation from DAC version is considered less physiological than pulsed release from non-DAC version
- Expected to return to Category 1 compounding status per 2026 reclassification
- Requires monitoring of IGF-1, blood sugar, and other metabolic markers
- Not appropriate for individuals with active cancer
Too many clinics, not enough clarity?
We don't sell peptides. Tell us your goals and we'll connect you with a vetted provider who can figure out what actually makes sense for you.
See what's right for youExplore other peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management. One of the most well-studied peptides available.
Tirzepatide
A dual GIP/GLP-1 receptor agonist that has shown even greater weight loss results than semaglutide in head-to-head trials.
BPC-157
A synthetic peptide derived from human gastric juice, studied primarily in animal models for its regenerative and anti-inflammatory properties. Not FDA-approved.
CJC-1295 / Ipamorelin
A commonly paired combination of growth hormone-releasing peptides used to stimulate natural GH production for anti-aging, body composition, and recovery.